Moderna and Merck Race Toward 2027 FDA Approval for Personalized Cancer Vaccine

Moderna and Merck are accelerating toward a potential 2027 FDA submission for their personalized cancer vaccine, according to Moderna CEO Stéphane Bancel. The announcement came during the European Society for Medical Oncology (ESMO) conference, where the companies presented new data underscoring the therapy's promise in treating melanoma. The vaccine, based on the same mRNA technology used in COVID-19 shots, is designed to prime the immune system against patient-specific tumor mutations. In clinical trials, combining the vaccine with Merck's Keytruda significantly reduced the risk of recurrence or death in high-risk melanoma patients. The companies are now planning a confirmatory Phase 3 trial to support regulatory approval. If successful, this would mark the first personalized mRNA cancer vaccine to reach the market, potentially transforming oncology. The race to 2027 signals a new era in tailored cancer immunotherapy, with both firms investing heavily in manufacturing scale-up. For patients and investors alike, the next two years will be critical in determining whether this approach can deliver on its early promise.